Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : MPT0B390
CAS No.: 1817802-18-8
Catalog No.: PC-49104Not For Human Use, Lab Use Only.
MPT0B390 (B390) is a selective HDAC1/2 inhibitor and an effective inducer of metalloproteinase 3 (TIMP3), significantly upregulates TIMP3 expression in colorectal cancer cells.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $198 | In stock | |
| 10 mg | $328 | In stock | |
| 25 mg | $528 | In stock | |
| 50 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
MPT0B390 (B390) is a selective HDAC1/2 inhibitor and an effective inducer of metalloproteinase 3 (TIMP3), significantly upregulates TIMP3 expression in colorectal cancer cells.
MPT0B390 exhibits potent antiproliferative activity against human colon cancer cell line HCT116 with IC50 of 0.03 uM.
MPT0B390 has lower IC50 and greater effect when compared with other commonly used HDAC1/2 inhibitor, SAHA.
MPT0B390 inhibits cell growth of MIA PaCa-2 with IC50 of 0.53 uM, with no effect on normal human pancreatic ductal epithelial cell line (HPDE-E6E7).
MPT0B390 upregulates DUSP2 expression and decreases ERK phosphorylation MIA PaCa-2 cells, exert antitumor effects via reinforcement of DUSP2 expression.
MPT0B390 inhibits pancreatic cancer migration, EV-VEGF-C expression, and proliferation of lymphatic endothelial cells.
MPT0B390 (12.5 mg/kg) reduces tumor-associated lymphangiogenesis and tumor invasion, alleviates cancer malignancy in KPC orthotopic mouse model.
| M.Wt | 375.40 | |
| Formula | C17H17N3O5S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
(E)-N-hydroxy-3-(1-((4-methoxyphenyl)sulfonyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)acrylamide |
|
1. Huang HL, et al. Theranostics. 2019 Sep 18;9(22):6676-6689.
2. Pei-Chi Hou, et al. Cancer Res. 2017 Aug 15;77(16):4305-4316.
3. Chu-An Wang, et al. Mol Cancer Ther. 2021 Sep;20(9):1550-1560.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
